Dr. Nicholas Vogelzang, MD
Claim this profileComprehensive Cancer Centers of Nevada
Studies Prostate Cancer
Studies Solid Tumors
12 reported clinical trials
27 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
2Solid Tumors
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Nicholas Vogelzang, MD is currently running
sEphB4-HSA + Pembrolizumab
for Cancer
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients with specific solid tumors. There will be four cohorts in this trial: 1. Cohort A, phase II 2nd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. 2. Cohort B, phase II 3rd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. 3. Cohort C, phase II neoadjuvant trial of sEphB4-HSA and pembrolizumab for locally advanced muscle invasive urothelial carcinoma. 4. Cohort D, phase II neoadjuvant trial of sEphB4-HSA and pembrolizumab for locally advanced prostate cancer.
Recruiting1 award Phase 223 criteria
Radium-223 + Docetaxel
for Prostate Cancer
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Recruiting2 awards Phase 323 criteria
More about Nicholas Vogelzang, MD
Clinical Trial Related5 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Nicholas Vogelzang, MD has experience with
- Abiraterone
- Enzalutamide
- ABM-1310
- Cobimetinib
- Xentuzumab
- Abemaciclib
Breakdown of trials Nicholas Vogelzang, MD has run
Prostate Cancer
BRAF Mutation
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nicholas Vogelzang, MD specialize in?
Nicholas Vogelzang, MD focuses on Prostate Cancer and Solid Tumors. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Nicholas Vogelzang, MD currently recruiting for clinical trials?
Yes, Nicholas Vogelzang, MD is currently recruiting for 2 clinical trials in Las Vegas Nevada. If you're interested in participating, you should apply.
Are there any treatments that Nicholas Vogelzang, MD has studied deeply?
Yes, Nicholas Vogelzang, MD has studied treatments such as Abiraterone, Enzalutamide, ABM-1310.
What is the best way to schedule an appointment with Nicholas Vogelzang, MD?
Apply for one of the trials that Nicholas Vogelzang, MD is conducting.
What is the office address of Nicholas Vogelzang, MD?
The office of Nicholas Vogelzang, MD is located at: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada 89169 United States. This is the address for their practice at the Comprehensive Cancer Centers of Nevada.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.